FDA Opens the U.S. to In Vivo Prime Editing
The U.S. FDA cleared Prime Medicine’s investigational new drug application for PM577a, an LNP-delivered in vivo Prime Editor targeting the ATP7B H1069Q mutation in Wilson disease. Together with New Zealand clearance in June, the…
